Twenty-Year Life Sciences Commercial Leader joins Virgo to Scale Clinical Trial Acceleration Platform

Commencement of regulatory pathway for U.S. market approval

First closing of Series A round and onboarding of top biotech leaders to fuel growth in 2022

H.C. Wainwright Bioconnect Conference - Jan. 10, 2022; Biotech Showcase 2022 Conference - Jan. 10, 2022

Hyris is going to present its new test to detect the body's T Cell immune response to SARS-CoV-2 on 17 December 2021, at "A-WISH", Alicante-Winter Immunology Symposium in Health, which will address strategies for the COVID-19 response and the development of the vaccines against SARS-CoV-2. This new solution leverages the Hyris System™, a proprietary platform that enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.

Scientists will assess the potential of psychedelic compounds for treating addiction

Swiss Life Sciences Group Plc (SLSG) has identified a need in the fast-growing cannabis and CBD industry to establish a financing and credit facility for companies and brands, especially those in the medical and pharmaceutical sector.

Sambrosa is going head to head with competitors to uphold and defend their title of having the best allergy decongestant

The biopharma technology company's AI-driven PhAROS™ platform has identified novel, plant-inspired formulations that will be tested using preclinical Zebrafish models at the National Research Council of Canada.

Hyris developed a rapid T-Cell test to track patients' immunity levels to SARS-CoV-2 for global clinical and research use after having inked an exclusive licensing agreement with Duke-NUS Medical School. This new solution leverages the power of the renowned HYRIS bCUBE™ and the whole Hyris SystemTM. This disruptive platform enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.

Hyris developed a rapid T-cell test to track patients' immunity levels to SARS-CoV-2 for global clinical use after having inked an exclusive licensing agreement with Duke-NUS Medical School. This new solution leverages the Hyris SystemTM, a proprietary platform that enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.

The eAdjudication® electronic endpoint adjudication platform is upgraded with an innovative Zoom connector that allows it to streamline the management of endpoint adjudication meetings, and safely and conveniently file meeting recordings and transcriptions within the platform.

Pro-ficiency was selected as a participant in the DPharm Idol Disrupt program, hosted at the Disruptive Innovations conference September 28-29, 2021.

The partnership provides a turnkey approach for workplaces, schools, major conventions, and other group events looking to ensure safety and meet governmental mandates for students, staff, employees, and event participants.

The new DICOM / PACS extension to the eAdjudication® electronic endpoint adjudication software brings on board the Orthanc server and a fully-equipped DICOM image viewer. This comprehensive solution facilitates the acquisition, storage, transmission and display of DICOM images for Expert Committees.

As new mutations of SARS-CoV-2 keep spreading worldwide, Hyris keeps monitoring its test kits effectiveness, performing routine analysis of SARS-CoV-2 variants to safeguard public health and the product's quality by assessing the potential impact of new strains on sensitivity and specificity.

Highlighting Gb Sciences' Development of Plant-Inspired Therapies for COVID-related Cytokine Release Syndrome, Chronic Pain, and Parkinson's Disease during the Healthcare & Biotech Track starting Monday, September 13.